Proactive Investors - Run By Investors For Investors

Redx Pharma Plc RNS Release

RXC004 pre-clinical profile

RNS Number : 4849Q
Redx Pharma plc
30 November 2016

30 November 2016



("Redx" or "the Company" or "the Group")


Pre-clinical profile of Porcupine inhibitor RXC004 presented at EORTC-NCI-AACR 2016


Redx, the drug development company, is pleased to announce that it will present the pre-clinical profile of its Porcupine inhibitor RXC004 at the 28th European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium in Munich, Germany, on 30 November 2016.


Redx's Porcupine inhibitor RXC004 exhibits potent and selective inhibition of the Wnt pathway in in vitro and in vivo models of Wnt dependant pancreatic cancer. Preliminary results indicate that RXC004 may also enhance the efficacy of checkpoint inhibitors, such as anti-PD-1 antibodies, by reducing the proportion of regulatory T cells in the tumour microenvironment and enhancing the ratio of cytotoxic T cells to regulatory T cells in tumour infiltrates.


Pre-clinical studies are ongoing to determine the effect of RXC004 on the immune response to cancer. The Company is progressing studies to prepare the RXC004 program for first-in-human clinical trials. The aim is to commence these, initially monotherapy, trials early 2017.


Dr Neil Murray, CEO of Redx, said:


"We're delighted to present the compelling pre-clinical profile of our Porcupine inhibitor RXC004 at the EORTC-NCI-AACR Symposium.


"RXC004 has the potential to become a potent therapy for a subset of biliary, gastric and pancreatic cancer patients. It has also been shown to enhance the efficacy of checkpoint inhibitors, such as anti-PD-1 antibodies. We aim to initiate first-in-human clinical studies for RXC004 early 2017." 


The Abstract (#305) for the Poster (P131) can be found on the EORTC-NCI-AACR Symposium website:


The Poster will be available on the Investor section of the Company's website:




For further information, please contact:


Redx Pharma Plc


Neil Murray, Chief Executive

T: +44 1625 469 900

Karl Hård, Head of Investor Relations &

Corporate Communications

T: +44 7491 651 406


Cantor Fitzgerald Europe (Nomad & Broker)


T: +44 20 7894 7000

Phil Davies/ Michael Reynolds






About Redx Pharma Plc

Company website:


Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a portfolio of 14 proprietary drug programs. Seven proof of concepts have been achieved across five programs, with relevance for respective therapies to treat MRSA, gonorrhoea, bone tumours, skin, brain, breast, pancreatic and blood cancers.






This information is provided by RNS
The company news service from the London Stock Exchange

Redx Pharma Plc Timeline

CN Research
April 06 2017

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use